Note: Patients may be seen more frequently as clinically indica ted. Patients who are unable or unwilling to return for follow-up evaluati ons may be followed via phone or email contact. Patients may be asked to send laboratory, imaging, and physician exam reports performed by their treating physician. At each scheduled follow-up evaluation, patients will undergo: x Physical examination, including ECOG (see Appendix B ) x Weight and vital signs x Toxicity assessment, including a review of systems x CBC w/differential x Acute Care Panel (sodium, potassium, chlori de, bicarbonate, creatinine, glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus ), Uric acid, Creatinine kinase, Lactate dehydrogenase, Total protein x Lymphocyte phenotyping (TBNK) x ȕ-HCG pregnancy test (serum or urine) on all women of child-bearing potential (complete at all follow-up evaluations within 120 days after the last vaccine) x Research samples, as described in Section 5.3. Approximately 72 mL of blood will be obtained at each follow-up visit. PBMC will be cryopreserved so that immunologic testing may be performed. This will be performed on protocol 03-C-0277. x Imaging studies as performed at baseline to determine tumor response. If clinically indicated, other scans or x-rays may be performed, e.g.